Clinical Trial Update: Radiolabeled Glass Beads (TheraSphere®) in Treating Patients With Primary Liver Cancer That Cannot Be Removed by Surgery [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating radiolabeled glass beads (TheraSphere) for unresectable primary liver cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• TheraSphere (yttrium-90 glass microspheres)

Snippet

Sponsor: Allan Tsung | Conditions: Liver Cancer | Phase 2 | Status: WITHDRAWN